Valuation: Adaptive Biotechnologies Corporation

Capitalization 2.05B 1.77B 1.62B 1.54B 2.83B 197B 2.87B 19.38B 7.5B 93.52B 7.71B 7.54B 326B P/E ratio 2026 *
-27.7x
P/E ratio 2027 * -51.6x
Enterprise value 1.94B 1.67B 1.52B 1.45B 2.67B 186B 2.71B 18.28B 7.07B 88.2B 7.27B 7.11B 307B EV / Sales 2026 *
6.75x
EV / Sales 2027 * 5.39x
Free-Float
98.16%
Yield 2026 *
-
Yield 2027 * -
1 day-2.66%
1 week-7.10%
Current month-9.01%
1 month-11.70%
3 months-20.01%
6 months-9.01%
Current year-21.00%
1 week 12.81
Extreme 12.81
14.1
1 month 12.81
Extreme 12.81
15.15
Current year 12
Extreme 12
19.8
1 year 8.5
Extreme 8.5
20.76
3 years 2.28
Extreme 2.28
20.76
5 years 2.28
Extreme 2.28
43.4
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2009-09-07
Chief Executive Officer 51 2009-09-07
Director of Finance/CFO 42 2024-04-07
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 2013-01-31
Director/Board Member 70 2013-11-30
Change 5d. change 1-year change 3-years change Capi.($)
-2.66%-7.10%+44.00%+97.69% 2.05B
-1.08%-4.80%+35.06%+53.31% 3.07B
-0.24%-5.41%-28.21%-31.43% 2.3B
-1.99%-4.70%+96.02%-55.99% 1.54B
-2.64%+1.88%+236.25% - 1.06B
-2.54%-8.48%+24.04%+139.45% 1.03B
-2.97%+27.25%-0.48%+31.85% 956M
-1.51%-4.91%-14.60%-17.96% 614M
-3.26%-14.43%+111.73%-72.33% 612M
-4.41%-5.71% - - 356M
Average -2.33%-5.02%+55.98%+18.07% 1.36B
Weighted average by Cap. -1.85%-5.26%+46.48%+26.67%

Financials

2026 *2027 *
Net sales 287M 247M 226M 215M 395M 27.54B 402M 2.71B 1.05B 13.07B 1.08B 1.05B 45.55B 352M 303M 277M 264M 484M 33.74B 492M 3.32B 1.28B 16.02B 1.32B 1.29B 55.8B
Net income -72.3M -62.21M -56.88M -54.27M -99.49M -6.94B -101M -682M -264M -3.29B -271M -266M -11.47B -38.59M -33.21M -30.36M -28.97M -53.11M -3.7B -53.99M -364M -141M -1.76B -145M -142M -6.12B
Net Debt -117M -100M -91.86M -87.65M -161M -11.2B -163M -1.1B -426M -5.32B -438M -429M -18.53B -157M -135M -123M -118M -215M -15.02B -219M -1.48B -572M -7.13B -587M -575M -24.84B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Employees
624
Date Price Change Volume
26-05-15 12.83 $ -2.66% 1,563,597
26-05-14 13.18 $ +0.38% 1,600,088
26-05-13 13.13 $ -3.67% 1,285,899
26-05-12 13.63 $ +0.66% 1,233,353
26-05-11 13.54 $ -1.96% 1,505,374
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
12.83USD
Average target price
20.14USD
Spread / Average Target
+57.00%

Quarterly revenue - Rate of surprise